Table 5.

Potential clinical implications of undocumented medications

Variable	Phase 1	Phase 2
Undocumented medications	443	78
Potential oral adverse effects
Xerostomia	187 (42.2)	31 (39.7)
Taste disturbance/metallic taste	88 (19.8)	11 (14.1)
Changes in salivary flow	42 (9.5)	5 (6.4)
Stress-induced hypoglycaemia with dental treatment	18 (4.1)	1 (1.3)
Stomatitis/mucositis	18 (4.1)	1 (1.3)
Mouth ulceration	17 (3.8)	0
Oral/oesophageal candidiasis	15 (3.4)	2 (2.6)
Angioedema of face, tongue, lips and mucous membranes	15 (3.4)	1 (1.3)
Gingival hyperplasia	14 (3.2)	3 (3.8)
Bruxism	12 (2.7)	2 (2.6)
Glossitis/tongue mucosal atrophy	11 (2.5)	2 (2.6)
Gingivitis/periodontitis	9 (2.0)	0
Dysphagia	7 (1.6)	0
Toothache	4 (0.9)	0
Dry throat/throat irritation	4 (0.9)	0
Burning mouth syndrome	3 (0.7)	0
Nausea	3 (0.7)	0
Sedation	3 (0.7)	0
Tongue discolouration/tongue coating	3 (0.7)	0
Tooth disorder	2 (0.5)	1 (1.3)
Ulcerative oesophagitis	2 (0.5)	0
Salivary gland swelling	1 (0.2)	0
Gingival haemorrhage	1 (0.2)	0
Osteonecrosis of the jaw	1 (0.2)	0
Local anaesthetic/vasoconstrictor precautions
Prolonged QT interval	21 (4.7)	5 (6.4)
Administer vasoconstrictor with caution and monitor vital signs	11 (2.5)	2 (2.6)
Monitor blood pressure before using local anaesthetic with vasoconstrictor	2 (0.5)	0
May result in tachycardia, peripheral vasodilation or hypotension	1 (0.2)	0
Effects on bleeding
Increased risk of bleeding	39 (8.8)	6 (7.7)
Prolonged bleeding time	33 (7.4)	1 (1.3)
Thrombocytopenia	13 (2.9)	3 (3.8)

Values are given as n or n (%).